Literature DB >> 29256471

Epidermal growth factor receptor: Role in human cancer.

Prashanth Rajaram1, Poornima Chandra2, Smriti Ticku1, B K Pallavi3, K B Rudresh1, Poorva Mansabdar1.   

Abstract

Cells are constantly exposed to various external stimuli which regulate the growth and survival of the cells. The signal transduction from the external environment to the interior of the cell is carried out by cell surface or transmembrane receptors. Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase and along with its ligands, EGFR is involved in the regulation of multiple cellular pathways. EGFR and its signaling pathway have been studied extensively for the biological and pathophysiological role in health and disease. There is enough evidence to suggest that EGFR is involved in the pathogenesis and progression of various cancers. This review discusses the structural anatomy and physiology of EGFR and its ligands, the role of EGFR in cancer and EGFR-targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29256471     DOI: 10.4103/ijdr.IJDR_534_16

Source DB:  PubMed          Journal:  Indian J Dent Res        ISSN: 0970-9290


  16 in total

1.  Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using 99mTc-MAG3-Cet-F(ab')2-Based SPECT/CT Imaging.

Authors:  Dai Shi; Yiqiu Zhang; Zhan Xu; Zhan Si; Yuan Cheng; Dengfeng Cheng; Guobing Liu
Journal:  Mol Imaging       Date:  2022-06-24       Impact factor: 3.250

2.  Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping.

Authors:  Yao Xiao; Gang Xu; Jordan M Cloyd; Shunda Du; Yilei Mao; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2022-05-04       Impact factor: 3.267

3.  Diffusion Reflection Method for Early Detection of Oral Squamous Cell Carcinoma Specifically Targeted by Circulating Gold-Nanorods Bio-Conjugated to Anti-Epidermal Growth Factor Receptor.

Authors:  Dror Fixler; Abraham Hirshberg; Shiran Sudri; Hamootal Duadi; Florin Altman; Irit Allon; Ariel Ashkenazy; Ruchira Chakraborty; Ilya Novikov
Journal:  Int J Nanomedicine       Date:  2021-03-17

4.  Exposure to chewing tobacco promotes primary oral squamous cell carcinoma and regional lymph node metastasis by alterations of SDF1α/CXCR4 axis.

Authors:  Sudipta Ray; Depanwita Saha; Neyaz Alam; Saunak Mitra Mustafi; Shyamsundar Mandal; Aniruddha Sarkar; Biswanath Majumder; Nabendu Murmu
Journal:  Int J Exp Pathol       Date:  2021-03-03       Impact factor: 1.925

5.  ZNF259 promotes breast cancer cells invasion and migration via ERK/GSK3β/snail signaling.

Authors:  Bin Liu; Xiaojing Xing; Xiang Li; Qianxue Guo; Tonghong Xu; Ke Xu
Journal:  Cancer Manag Res       Date:  2018-09-03       Impact factor: 3.989

Review 6.  Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.

Authors:  Simone Camelliti; Valentino Le Noci; Francesca Bianchi; Claudia Moscheni; Francesca Arnaboldi; Nicoletta Gagliano; Andrea Balsari; Marina Chiara Garassino; Elda Tagliabue; Lucia Sfondrini; Michele Sommariva
Journal:  J Exp Clin Cancer Res       Date:  2020-11-09

Review 7.  MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Authors:  Chao-Ju Chen; Yu-Peng Liu
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-06

Review 8.  Evaluation of TGF-β1 and EGFR in Cleft Affected Lip Mucosa.

Authors:  Olga Rimdenoka; Māra Pilmane
Journal:  Acta Med Litu       Date:  2021-03-25

9.  Identification and Verification of Core Genes in Colorectal Cancer.

Authors:  Houxi Xu; Yuzhu Ma; Jinzhi Zhang; Jialin Gu; Xinyue Jing; Shengfeng Lu; Shuping Fu; Jiege Huo
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

Review 10.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.